+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Antiglaucoma Drugs Global Market Report 2020

  • ID: 4852503
  • Report
  • Region: Global
  • 200 pages
  • The Business Research Company
1 of 5

FEATURED COMPANIES

  • Abbott Healthcare
  • Aerie Pharmaceuticals Inc
  • ALLERGAN
  • Bayer AG
  • Genentech Inc.
  • Johnson & Johnson
  • MORE

Antiglaucoma Drugs Market Global Report 2020 from the author provides strategists, marketers and senior management with the critical information they need to assess the global antiglaucoma drugs market.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Description:
Where is the largest and fastest growing market for the antiglaucoma drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Antiglaucoma Drugs Market Global Report from the author answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market

  • The Market Characteristics section of the report defines and explains the market.
  • The Market Size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
  • Market Segmentations break down market into sub markets.
  • The Regional and Country section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
  • Competitive Landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The Trends and Strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.

Scope

  • Markets Covered: 1) By Product Type: Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Combined Medication, Others 2) By Disease Condition Type: Open-Angle Glaucoma, Angle-Closure Glaucoma, Normal-Tension Glaucoma, Congenital Glaucoma, Other Types Of Glaucoma 3) By Type: Hospital Prescription drugs, Over-the counter drugs
  • Companies Mentioned: Aerie Pharmaceuticals, Inc., ALLERGAN, Novartis AG, Abbott Healthcare, Johnson & Johnson
  • Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA
  • Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
  • Time Series: Five years historic and forecast.
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Healthcare
  • Aerie Pharmaceuticals Inc
  • ALLERGAN
  • Bayer AG
  • Genentech Inc.
  • Johnson & Johnson
  • MORE

1. Executive Summary

2. Antiglaucoma Drugs Market Characteristics

3. Antiglaucoma Drugs Market Size And Growth
3.1. Global Antiglaucoma Drugs Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Antiglaucoma Drugs Forecast Market, 2019 - 2022F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market

4. Antiglaucoma Drugs Market Segmentation
4.1. Global Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

  • Alpha Agonist
  • Beta Blockers
  • Prostaglandin Analogs
  • Combined Medication
  • Others

4.2. Global Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

  • Open-Angle Glaucoma
  • Angle-Closure Glaucoma
  • Normal-Tension Glaucoma
  • Congenital Glaucoma
  • Other Types Of Glaucoma

4.3. Global Antiglaucoma Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

  • Hospital Prescription drugs
  • Over-the counter drugs

5. Antiglaucoma Drugs Market Regional And Country Analysis
5.1. Global Antiglaucoma Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
5.2. Global Antiglaucoma Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

6. Asia-Pacific Antiglaucoma Drugs Market
6.1. Asia-Pacific Antiglaucoma Drugs Market Overview
6.2. Asia-Pacific Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
6.3. Asia-Pacific Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

7. China Antiglaucoma Drugs Market
7.1. China Antiglaucoma Drugs Market Overview
7.2. China Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion
7.3. China Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion

8. India Antiglaucoma Drugs Market
8.1. India Antiglaucoma Drugs Market Overview
8.2. India Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
8.3. India Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

9. Japan Antiglaucoma Drugs Market
9.1. Japan Antiglaucoma Drugs Market Overview
9.2. Japan Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
9.3. Japan Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

10. Australia Antiglaucoma Drugs Market
10.1. Australia Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
10.2. Australia Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

11. Indonesia Antiglaucoma Drugs Market
11.1. Indonesia Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
11.2. Indonesia Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

12. South Korea Antiglaucoma Drugs Market
12.1. South Korea Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
12.2. South Korea Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

13. Western Europe Antiglaucoma Drugs Market
13.1. Western Europe Antiglaucoma Drugs Market Overview
13.2. Western Europe Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
13.3. Western Europe Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

14. UK Antiglaucoma Drugs Market
14.1. UK Antiglaucoma Drugs Market Overview
14.2. UK Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
14.3. UK Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

15. Germany Antiglaucoma Drugs Market
15.1. Germany Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
15.2. Germany Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

16. France Antiglaucoma Drugs Market
16.4. France Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
16.5. France Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

17. Eastern Europe Antiglaucoma Drugs Market
17.1. Eastern Europe Antiglaucoma Drugs Market Overview
17.2. Eastern Europe Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
17.3. Eastern Europe Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

18. Russia Antiglaucoma Drugs Market
18.1. Russia Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
18.2. Russia Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

19. North America Antiglaucoma Drugs Market
19.1. North America Antiglaucoma Drugs Market Overview
19.2. North America Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
19.3. North America Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

20. USA Antiglaucoma Drugs Market
20.1. USA Antiglaucoma Drugs Market Overview
20.2. USA Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
20.3. USA Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

21. South America Antiglaucoma Drugs Market
21.1. South America Antiglaucoma Drugs Market Overview
21.2. South America Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
21.3. South America Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

22. Brazil Antiglaucoma Drugs Market
22.1. Brazil Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
22.2. Brazil Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

23. Middle East Antiglaucoma Drugs Market
23.1. Middle East Antiglaucoma Drugs Market Overview
23.2. Middle East Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
23.3. Middle East Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

24. Africa Antiglaucoma Drugs Market
24.1. Africa Antiglaucoma Drugs Market Overview
24.2. Africa Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
24.3. Africa Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

25. Antiglaucoma Drugs Market Competitive Landscape And Company Profiles
25.1. Antiglaucoma Drugs Market Competitive Landscape
25.2. Antiglaucoma Drugs Market Company Profiles
25.2.1. Aerie Pharmaceuticals, Inc
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. ALLERGAN
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. Novartis AG
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. Abbott Healthcare
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. Johnson & Johnson
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Antiglaucoma Drugs Market

27. Antiglaucoma Drugs Market Trends And Strategies

28. Product Pipeline Analysis

29. Antiglaucoma Drugs Market Future Outlook and Potential Analysis

30. Appendix
30.1. Abbreviations
30.2. Currencies
30.3. Research Inquiries

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abbott Healthcare
  • Aerie Pharmaceuticals Inc
  • ALLERGAN
  • Bayer AG
  • Genentech Inc.
  • Johnson & Johnson
  • MORE
The antiglaucoma drug market consists of sales of antiglaucoma drugs which are used in the treatment of glaucoma. Glaucoma is a disease in which the optic nerve is damaged resulting into irreversible loss of vision and it is often associated with increased pressure of the fluid in eye. The market comprises of segments such as alpha agonists, beta blockers, prostaglandins, combined medication and other. The market does not include the sale of biologics used for the treatment of glaucoma.

The global antiglaucoma drugs market was valued at about $15.62 billion in 2018 and is expected to grow to $20.57 billion at a CAGR of 7.1% through 2022.

The antiglaucoma drugs market has been geographically segmented into North America, Western Europe, Asia-Pacific, Eastern Europe, South America and Middle East & Africa. The North American Market is the largest market for antiglaucoma drugs and is expected to continue to do so during the forecast period.

Incidence of glaucoma increases with age and due to increase in the geriatric population worldwide, governments are launching initiatives to promote awareness on glaucoma and other eye disorders. For instance, the Vision Health initiative by Centers for Disease Control and Prevention (CDC) in the USA aimed to prevent eye disorders including glaucoma and improve the overall eye health. In Australia, the government funded an eye screening program as part of its Vision 2020 initiative to promote awareness and prevent vision loss among the population suffering from glaucoma and other eye disorders. These government initiatives will stimulate the awareness among the people on glaucoma driving the market for anti-glaucoma drugs.

Anti-glaucoma drugs are facing the risk of patent expiration in the USA and Europe. For instance, travaprost and bimatoprost, which are used in the treatment of glaucoma, will lose its patent in 2021. This will result in the launch of generic form of the drugs that are priced lower than branded drugs thereby reducing the overall market growth.

Companies in the antiglaucoma drugs market are developing combination therapies in the treatment of glaucoma disease due to their ability to lower intraocular pressure in glaucoma patients. Most of the combinations therapies are fixed dose drugs as it offers patient the ease of consumption when compared to non-fixed combinations. In 2017, Alcon launched a combination drug, Simbrinza which is fixed combination of Brinzolamide and Brimonidine, to help patients in reducing the intake of multiple drugs for glaucoma.

To get an antiglaucoma drug approved by the United States Food and Drug Administration (USFDA), drug should have comparable intraocular pressure (IOP) lowering efficacy and benefit-to-hazard ration with respect to the benchmark drug. In 2018, Rhopressa (netarsudil) Ophthalmic Solution by Aerie Pharmaceuticals Inc., was approved by the US FDA considering its ability to lower IOP when compared to benchmarked drugs for glaucoma in the market.

In 2018, Astellas Pharma Inc. acquired Quethera Ltd., a gene therapy company based in the UK. With this acquisition, Astellas has gained authority over Quethera's ophthalmic gene therapy program which focuses on developing novel treatment for ocular diseases such as glaucoma.

Major players in the market are Aerie Pharmaceuticals, Inc., ALLERGAN, Novartis AG, Abbott Healthcare and Johnson & Johnson.
Note: Product cover images may vary from those shown
5 of 5
  • Aerie Pharmaceuticals Inc
  • ALLERGAN
  • Novartis AG
  • Abbott Healthcare
  • Johnson & Johnson
  • Merck & Co
  • Genentech Inc.
  • Pfizer Inc.
  • Bayer AG
  • Santen Pharmaceuticals Company Ltd.
  • Regeneron Pharmaceuticals Inc.
  • Valeant Phar
Note: Product cover images may vary from those shown
6 of 5

Loading
LOADING...

Adroll
adroll